STAAR Surgical Company
NASDAQ:STAAMedical - Instruments & Supplies
-$0.40 today
- Market cap
- $1.27B
- Beta
- 1.23
- P/E (TTM)
- -68.3
- EPS (TTM)
- -$0.42
Volume 0.45M
Average 1.07M
STAA Operating Cash Flow
Cash generated by the company's core business operations during the period.
STAAR Surgical CompanyNASDAQ: STAA
Operating Cash Flow · Q1 FY2026 · quarter ended Apr 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $21.7M (cash outflow) rose 278.4% year over year, behind the +329.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 454.3% from the prior quarter.
Context
- Operating cash flow amounted to 14.3% of revenue in FY2025, up 9.3 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +278.4% toward the trailing-twelve-month pace of +329.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (34.23M) USD
- Year-over-year change
- -317.7%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | (34.23M) | -317.7% |
| FY2024 | 2024-12-27 | 15.73M | +7.7% |
| FY2023 | 2023-12-29 | 14.59M | -59.1% |
| FY2022 | 2022-12-30 | 35.72M | -18.8% |
| FY2021 | 2021-12-31 | 43.96M | — |
Operating Cash Flow vs competitors
How STAA compares with its peers on the latest reported figures
- STAA's LTM Apr 2026 operating cash flow of $50.19M is the 4th largest of the 5 companies compared; the peer median is $745.85M.
- Its year-over-year change of +329.4% is the highest of 5, against a peer median of +20.3%.
- Operating cash flow amounts to 17.3% of revenue for STAA, versus a peer median of 17.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.34B | +14.1% | +23.1% | 21.4% | |
| LTM Jul 2026 | $1.03B | +26.6% | +4.8% | 24.4% | |
| LTM Jun 2026 | $458.39M | +146.4% | -6.4% | 8.6% | |
| LTM Apr 2026 | $50.19M | +329.4% | — | 17.3% | |
| LTM Mar 2026 | $17.57M | +6.7% | -35.9% | 13.8% | |
| Peer median (excluding STAA) | $745.85M | +20.3% | -0.8% | 17.6% | |
Competitors are the stored peer set for STAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | 27.51M | 39.01M | 21.35M | (20.21M) | (80.45M) |
| Depreciation & Amortization | 3.64M | 4.51M | 5.12M | 6.89M | 8.32M |
| Deferred Income Tax | (1.52M) | (1.34M) | 3.26M | 3.59M | (2.92M) |
| Stock-Based Compensation | 14.61M | 20.37M | 23.52M | 27.21M | 30.59M |
| Change in Working Capital | (2.39M) | (29.13M) | (40.84M) | (5.4M) | (16.33M) |
| Accounts Receivables | (8.87M) | (19.6M) | (32.76M) | 16.49K | 27.83M |
| Inventory | 66K | (7.94M) | (14.36M) | (10K) | (16.98M) |
| Accounts Payables | 108K | 1.81M | (701K) | 75 | (5.51M) |
| Other Working Capital | 6.3M | (3.39M) | 6.98M | (5.41M) | (21.67M) |
| Other Non-Cash Items | 2.11M | 2.3M | 2.18M | 3.64M | 26.55M |
| Operating Cash Flow | 43.96M | 35.72M | 14.59M | 15.73M | (34.23M) |
| Capital Expenditures | (13.65M) | (18.11M) | (18.19M) | (23.39M) | (5.82M) |
| Acquisitions (Net) | 0 | 138.27M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (155.75M) | (52.31M) | (80.24M) | (75.36M) |
| Sales of Investments | 0 | 17.48M | 144.85M | 44.42M | 127.32M |
| Other Investing Activities | 0 | (138.27M) | 0 | 0 | 198K |
| Investing Cash Flow | (13.65M) | (156.38M) | 74.35M | (59.22M) | 46.34M |
| Debt Repayment | (1.65M) | (126K) | (161K) | (165K) | (42K) |
| Common Stock Issued | 1K | 1K | 1K | 2K | 3.47M |
| Common Stock Repurchased | 0 | 0 | (2.1M) | (1.51M) | (6.46M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.44M | 8.42M | 9.67M | 7.39M | (1.52M) |
| Financing Cash Flow | 17.79M | 8.3M | 7.42M | 5.72M | (4.56M) |
| Effect of Forex Changes | (857K) | (862K) | 202K | (1.11M) | 1.44M |
| Net Change in Cash | 47.25M | (113.23M) | 96.56M | (38.88M) | 8.99M |
| Free Cash Flow | 30.32M | 17.61M | (3.59M) | (7.67M) | (40.05M) |
STAAR Surgical Company
NASDAQ:STAA
Intrinsic Alpha fair value
Locked
Current Price
$25.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.